3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip

Abstract

Decades of efforts in engineering in vitro cancer models have advanced drug discovery and the insight into cancer biology. However, the establishment of preclinical models that enable fully recapitulating the tumor microenvironment remains challenging owing to its intrinsic complexity. Recent progress in engineering techniques has allowed the development of a new generation of in vitro preclinical models that can recreate complex in vivo tumor microenvironments and accurately predict drug responses, including spheroids, organoids, and tumor‐on‐a‐chip. These biomimetic 3D tumor models are of particular interest as they pave the way for better understanding of cancer biology and accelerating the development of new anticancer therapeutics with reducing animal use. Here, the recent advances in developing these in vitro platforms for cancer modeling and preclinical drug screening, focusing on incorporating hydrogels are reviewed to reconstitute physiologically relevant microenvironments. The combination of spheroids/organoids with microfluidic technologies is also highlighted to better mimic in vivo tumors and discuss the challenges and future directions in the clinical translation of such models for drug screening and personalized medicine.

Enhancing drug penetration in solid tumors via nanomedicine: Evaluation models, strategies and perspectives

“…Tumor heterogeneity is credited to significant differences in tumor proliferation and invasion [ 74 ], and the model to address tumor heterogeneity is critical for assessing nanomedicine for tumor diagnosis and treatment. To pursue an animal model that mimics a complex and realistic physiological or pathological environment in patient [ 75 ], patient-derived xenograft (PDX) models have been developed, and they have a number of advantages. The PDX model is built by transplanting tumor tissues from patients into critically immunodeficient mice.…”

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

“…There are various advantages of the 3D organoids model (Table 4 ). One of the major advantages of 3D organoids is their ability to recreate complex tumor microenvironments in a controlled laboratory environment [ 103 ]. 3D organoids provide a more physiologically relevant model for assessing the effects of PI3K inhibitors.…”

In Vitro Glioblastoma Model on a Plate for Localized Drug Release Study from a 3D-Printed Drug-Eluted Hydrogel Mesh

“…Bioengineered tumor models, particularly tumoroid-based in vitro models, have shown promise in evaluating the efficacy of current anticancer drugs and the development of new therapies [33,34]. Tumor spheroids have the potential to create higher-order cellular tissue organization and better replicate the real tissue microenvironment [35].…”